Somatostatin receptor expression in Merkel cell carcinoma: correlation with clinical data

References

• Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89(1):1–4. doi: 10.1002/jso.20167.
   PubMed Web of Science ®Google Scholar
• Akaike T, Qazi J, Anderson A, et al. High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic merkel cell carcinoma. Br J Dermatol. 2021;184(2):319–327. doi: 10.1111/bjd.19150.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Lebbé C, Zur Hausen A, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53–69. doi: 10.1016/j.ejca.2016.10.022.
   PubMed Web of Science ®Google Scholar
• Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457–463.e2. doi: 10.1016/j.jaad.2017.10.028.
   PubMed Web of Science ®Google Scholar
• Survival Rates for Merkel Cell Carcinoma [Internet]. 2022 [cited 2022 May 4]. Available from: https://www.cancer.org/cancer/merkel-cell-skin-cancer/detection-diagnosis-staging/survival-rates.html#references.
   Google Scholar
• Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37(1):20–27. doi: 10.1111/j.1600-0560.2009.01370.x.
   PubMed Web of Science ®Google Scholar
• Youlden DR, Soyer HP, Youl PH, et al. Incidence and survival for merkel cell carcinoma in Queensland, Australia, 1993-2010. JAMA Dermatol. 2014;150(8):864–872. doi: 10.1001/jamadermatol.2014.124.
   PubMed Web of Science ®Google Scholar
• Sihto H, Kukko H, Koljonen V, et al. Clinical factors associated with merkel cell polyomavirus infection in merkel cell carcinoma. J Natl Cancer Inst. 2009;101(13):938–945. doi: 10.1093/jnci/djp139.
   PubMedGoogle Scholar
• Zur Hausen A, Rennspiess D, Winnepenninckx V, et al. Early B-Cell differentiation in merkel cell carcinomas: clues to cellular ancestry. Cancer Res. 2013;73(16):4982–4987. doi: 10.1158/0008-5472.CAN-13-0616.
   PubMed Web of Science ®Google Scholar
• Moshiri AS, Doumani R, Yelistratova L, et al. Polyomavirus-Negative merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. J Invest Dermatol. 2017;137(4):819–827. doi: 10.1016/j.jid.2016.10.028.
   PubMed Web of Science ®Google Scholar
• Harms PW, Harms KL, Moore PS, et al. The biology and treatment of merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol. 2018;15(12):763–776. doi: 10.1038/s41571-018-0103-2.
   PubMed Web of Science ®Google Scholar
• Sihto H, Kukko H, Koljonen V, et al. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in merkel cell carcinoma. Clin Cancer Res. 2011;17(14):4806–4813. doi: 10.1158/1078-0432.CCR-10-3363.
   PubMed Web of Science ®Google Scholar
• Rossi V, di Zazzo E, Galasso G, et al. Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells. Front Pharmacol. 2019;10:28. doi: 10.3389/fphar.2019.00028.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228–252. doi: 10.1016/j.yfrne.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Öberg KE, Reubi J, Kwekkeboom DJ, et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139(3):742–753.e1. doi: 10.1053/j.gastro.2010.07.002.
   PubMed Web of Science ®Google Scholar
• Zou YI, Tan H, Zhao Y, et al. Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncol Lett. 2019;17(2):1723–1731. doi: 10.3892/ol.2018.9773.
   PubMed Web of Science ®Google Scholar
• Buder K, Lapa C, Kreissl MC, et al. Somatostatin receptor expression in merkel cell carcinoma as target for molecular imaging. BMC Cancer. 2014;14(1):268. doi: 10.1186/1471-2407-14-268.
   PubMedGoogle Scholar
• Giovannini E, Giovacchini G, Borsò E, et al. [68Ga]-dota peptide PET/CT in neuroendocrine tumors: main clinical applications. Curr Radiopharm. 2019;12(1):11–22. doi: 10.2174/1874471012666181212101244.
   PubMed Web of Science ®Google Scholar
• Yoo J, Kim SH, Jeon SK, et al. Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort. Eur Radiol. 2021;31(10):7734–7745. doi: 10.1007/s00330-021-07859-0.
   PubMed Web of Science ®Google Scholar
• Rinzivillo M, de Felice I, Magi L, et al. Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. J Gastrointest Oncol. 2021;12(2):845–855. doi: 10.21037/jgo-20-292.
   PubMed Web of Science ®Google Scholar
• Delpassand ES, Tworowska I, Esfandiari R, et al. Targeted α-Emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-Expressing neuroendocrine tumors: first-in-Humans Dose-Escalation clinical trial. J Nucl Med. 2022;63(9):1326–1333. doi: 10.2967/jnumed.121.263230.
   PubMed Web of Science ®Google Scholar
• Askari E, Moghadam SZ, Wild D, et al. Peptide receptor radionuclide therapy in merkel cell carcinoma: a comprehensive review. J Nucl Med Technol. 2023;51(1):22–25. doi: 10.2967/jnmt.122.264904.
   PubMed Web of Science ®Google Scholar
• Orlova KV, Delektorskaya VV, Vishnevskaya YV, et al. Somatostatin receptor type 2 expression in merkel cell carcinoma as a prognostic factor. J Eur Acad Dermatol Venereol. 2018;32(6):e236–7–e237. doi: 10.1111/jdv.14769.
   Web of Science ®Google Scholar
• Gardair C, Samimi M, Touzé A, et al. Somatostatin receptors 2A and 5 are expressed in merkel cell carcinoma with no association with disease severity. Neuroendocrinology. 2015;101(3):223–235. doi: 10.1159/000381062.
   PubMed Web of Science ®Google Scholar
• Sundqvist B, Sihto H, von Willebrand M, et al. LRIG1 is a positive prognostic marker in merkel cell carcinoma and merkel cell carcinoma expresses epithelial stem cell markers. Virchows Arch. 2021;479(6):1197–1207. doi: 10.1007/s00428-021-03158-7.
   PubMed Web of Science ®Google Scholar
• Brierley J, Gospodarowicz M, Wittekind C, et al. TNM classification of malignant tumours. Eight edit. ÓSullivan O, Mason M, Asamura H, Lee A, van Eycken E, Denny L editors. Oxford: John Wiley & Sons, Ltd; 2017. p.147–149.
   Google Scholar
• Jaatinen J, Veija T, Salmikangas M, et al. ALK is frequently phosphorylated in merkel cell carcinoma and associates with longer survival. PLoS One. 2021;16(5):e0252099. doi: 10.1371/journal.pone.0252099.
   PubMed Web of Science ®Google Scholar
• Remes SM, Leijon HL, Vesterinen TJ, et al. Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias. J Histochem Cytochem. 2019;67(10):735–743. doi: 10.1369/0022155419856900.
   PubMed Web of Science ®Google Scholar
• Majala S, Vesterinen T, Seppänen H, et al. Correlation of somatostatin receptor 1–5 expression, [68ga]ga-dotanoc, [18f]f-fdg pet/ct and clinical outcome in a prospective cohort of pancreatic neuroendocrine neoplasms. Cancers. 2022;14(1):162. doi: 10.3390/cancers14010162.
   Web of Science ®Google Scholar
• Vesterinen T, Leijon H, Mustonen H, et al. Somatostatin receptor expression is associated with metastasis and patient outcome in pulmonary carcinoid tumors. J Clin Endocrinol Metab. 2019;104(6):2083–2093. doi: 10.1210/jc.2018-01931.
   PubMed Web of Science ®Google Scholar
• Leijon H, Remes S, Hagström J, et al. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol. 2019;86:66–75. doi: 10.1016/j.humpath.2018.11.020.
   PubMed Web of Science ®Google Scholar
• Storvall S, Leijon H, Ryhänen E, et al. Somatostatin receptor expression in parathyroid neoplasms. Endocr Connect. 2019;8(8):1213–1223. doi: 10.1530/EC-19-0260.
   PubMed Web of Science ®Google Scholar
• Treppiedi D, Jobin ML, Peverelli E, et al. Single-Molecule microscopy reveals dynamic FLNA interactions governing SSTR2 clustering and internalization. Endocrinology. 2018;159(8):2953–2965. doi: 10.1210/en.2018-00368.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Treppiedi D, Giardino E, et al. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. Endocr Relat Cancer. 2019;26(2):R95–R108. doi: 10.1530/ERC-18-0442.
   PubMed Web of Science ®Google Scholar
• Bedolla RG, Wang Y, Asuncion A, et al. Nuclear versus cytoplasmic localization of filamin a in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res. 2009;15(3):788–796. doi: 10.1158/1078-0432.CCR-08-1402.
   PubMed Web of Science ®Google Scholar
• Garneski KM, Warcola AH, Feng Q, et al. Merkel cell polyomavirus is more frequently present in North American than Australian merkel cell carcinoma tumors. J Invest Dermatol. 2009;129(1):246–248. doi: 10.1038/jid.2008.229.
   PubMed Web of Science ®Google Scholar
• Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389–427. doi: 10.1210/er.2002-0007.
   PubMed Web of Science ®Google Scholar
• Guida M, D’Alò A, Mangia A, et al. Somatostatin receptors in Merkel-Cell carcinoma: a therapeutic opportunity using somatostatin analog alone or in association with checkpoint inhibitors immunotherapy. A case report. Front Oncol. 2020;10:1073. doi: 10.3389/fonc.2020.01073.
   PubMed Web of Science ®Google Scholar
• Majala S, Seppänen H, Kemppainen J, et al. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT. EJNMMI Res. 2019;9(1):116. doi: 10.1186/s13550-019-0585-7.
   PubMed Web of Science ®Google Scholar
• Wang A, Yuan Y, Chu H, et al. Somatostatin receptor 2: a potential predictive biomarker for immune checkpoint inhibitor treatment. Pathol Oncol Res. 2022;28:1610196. doi: 10.3389/pore.2022.1610196.
   PubMed Web of Science ®Google Scholar
• Fotouhi O, Zedenius J, Höög A, et al. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors. Neuro Endocrinol Lett. 2018;39(4):305–309.
   PubMed Web of Science ®Google Scholar